{"filing":{"accession_number":"0001193125-26-296190","cik":"0001754068","ticker":"KLRS","company_name":"Kalaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"d34897d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/d34897d8k.htm"},"events":[{"id":17056,"run_id":15270,"accession_number":"0001193125-26-296190","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15357,"accession_number":"0001193125-26-296190","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:22.408799+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15357,"accession_number":"0001193125-26-296190","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:22.408799+00:00","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-06"}]}